Spine Volumetric BMD and Strength in Premenopausal Idiopathic Osteoporosis: Effect of Teriparatide Followed by Denosumab.

Agarwal S, Shane E, Lang T, Shiau S, Kamanda-Kosseh M, Bucovsky M, Lappe JM, Stubby J, Recker RR, Hu Y, Wang Z, Edward Guo X, Cohen A

The Journal of clinical endocrinology and metabolism1 Jun 2022Cited by 7 (Europe PMC)

PMID35428889PMCIDPMC9391607DOI10.1210/clinem/dgac232PepBankPUB-35428889

Source link PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, lumbar trabecular vBMD increased after teriparatide.
In plain wordsIn premenopausal women with idiopathic osteoporosis, lumbar trabecular bone density increased after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePost-teriparatide lumbar trabecular vBMD
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mcg daily · 24 monthsAs given in this study (human).
Measurements
Trabecular vBMD change
25%
After teriparatide
Source sentences
Summary
There were large increases (all Ps < 0.001) in trabecular vBMD (25%), other vBMD parameters, and stiffness (21%) after teriparatide.
3 context sentences(design, population, supporting numbers)
Summary · context
Ancillary analysis of baseline, post-teriparatide, and post-denosumab cQCT scans from a randomized trial of 41 women allocated to teriparatide (20 mcg daily; n = 28) or placebo (n = 11).
Summary · context
After 6 months, those on teriparatide continued for 18 months, and those on placebo switched to teriparatide for 24 months.
Summary · context
After completing teriparatide, 33 enrolled in a Phase 2B extension with denosumab (60 mg every 6 months) for 12 months.
Report a problemFND-3542888901
02HumanNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, lumbar stiffness increased significantly after teriparatide.
In plain wordsIn premenopausal women with idiopathic osteoporosis, lumbar bone stiffness increased significantly after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePost-teriparatide lumbar stiffness
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mcg daily · 24 monthsAs given in this study (human).
Measurements
Stiffness change
21%
After teriparatide
Source sentences
Summary
There were large increases (all Ps < 0.001) in trabecular vBMD (25%), other vBMD parameters, and stiffness (21%) after teriparatide.
3 context sentences(design, population, supporting numbers)
Summary · context
Ancillary analysis of baseline, post-teriparatide, and post-denosumab cQCT scans from a randomized trial of 41 women allocated to teriparatide (20 mcg daily; n = 28) or placebo (n = 11).
Summary · context
After 6 months, those on teriparatide continued for 18 months, and those on placebo switched to teriparatide for 24 months.
Summary · context
After completing teriparatide, 33 enrolled in a Phase 2B extension with denosumab (60 mg every 6 months) for 12 months.
Report a problemFND-3542888903
03HumanNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, other lumbar vBMD parameters increased significantly after teriparatide.
In plain wordsIn premenopausal women with idiopathic osteoporosis, other lumbar bone-density parameters increased significantly after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePost-teriparatide other lumbar vBMD parameters
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mcg daily · 24 monthsAs given in this study (human).
Source sentences
Summary
There were large increases (all Ps < 0.001) in trabecular vBMD (25%), other vBMD parameters, and stiffness (21%) after teriparatide.
3 context sentences(design, population, supporting numbers)
Summary · context
Ancillary analysis of baseline, post-teriparatide, and post-denosumab cQCT scans from a randomized trial of 41 women allocated to teriparatide (20 mcg daily; n = 28) or placebo (n = 11).
Summary · context
After 6 months, those on teriparatide continued for 18 months, and those on placebo switched to teriparatide for 24 months.
Summary · context
After completing teriparatide, 33 enrolled in a Phase 2B extension with denosumab (60 mg every 6 months) for 12 months.
Report a problemFND-3542888902

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

04HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, lumbar trabecular vBMD increased during denosumab after teriparatide.
In plain wordsIn premenopausal women with idiopathic osteoporosis, lumbar trabecular bone density increased during denosumab after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePost-denosumab lumbar trabecular vBMD
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Trabecular vBMD change
10%
After denosumab
Source sentences
Summary
Statistically significant increases in trabecular vBMD (10%; P < 0.001) and other vBMD parameters (P = 0.03-0.001) were seen after denosumab, while stiffness increased by 7% (P = 0.068).
3 context sentences(design, population, supporting numbers)
Summary · context
Ancillary analysis of baseline, post-teriparatide, and post-denosumab cQCT scans from a randomized trial of 41 women allocated to teriparatide (20 mcg daily; n = 28) or placebo (n = 11).
Summary · context
After 6 months, those on teriparatide continued for 18 months, and those on placebo switched to teriparatide for 24 months.
Summary · context
After completing teriparatide, 33 enrolled in a Phase 2B extension with denosumab (60 mg every 6 months) for 12 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3542888904
05HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, stiffness rose nonsignificantly during denosumab after teriparatide.
In plain wordsIn premenopausal women with idiopathic osteoporosis, stiffness increased without statistical significance during denosumab after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePost-denosumab lumbar stiffness
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Stiffness change
7%
After denosumab
Source sentences
Summary
Statistically significant increases in trabecular vBMD (10%; P < 0.001) and other vBMD parameters (P = 0.03-0.001) were seen after denosumab, while stiffness increased by 7% (P = 0.068).
3 context sentences(design, population, supporting numbers)
Summary · context
Ancillary analysis of baseline, post-teriparatide, and post-denosumab cQCT scans from a randomized trial of 41 women allocated to teriparatide (20 mcg daily; n = 28) or placebo (n = 11).
Summary · context
After 6 months, those on teriparatide continued for 18 months, and those on placebo switched to teriparatide for 24 months.
Summary · context
After completing teriparatide, 33 enrolled in a Phase 2B extension with denosumab (60 mg every 6 months) for 12 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3542888906
06HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, sequential teriparatide and denosumab significantly increased lumbar trabecular vBMD.
In plain wordsIn premenopausal women with idiopathic osteoporosis, sequential teriparatide and denosumab significantly increased lumbar trabecular bone density.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSequential treatment lumbar trabecular vBMD
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Trabecular vBMD change
43%
Sequential treatment
Source sentences
Summary
Sequential teriparatide and denosumab led to highly significant (all Ps < 0.001) increases LS trabecular vBMD (43%), other vBMD parameters (15-31%), and stiffness (21%).
3 context sentences(design, population, supporting numbers)
Summary · context
Ancillary analysis of baseline, post-teriparatide, and post-denosumab cQCT scans from a randomized trial of 41 women allocated to teriparatide (20 mcg daily; n = 28) or placebo (n = 11).
Summary · context
After 6 months, those on teriparatide continued for 18 months, and those on placebo switched to teriparatide for 24 months.
Summary · context
After completing teriparatide, 33 enrolled in a Phase 2B extension with denosumab (60 mg every 6 months) for 12 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3542888907
07HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, sequential teriparatide and denosumab significantly increased lumbar stiffness.
In plain wordsIn premenopausal women with idiopathic osteoporosis, sequential teriparatide and denosumab significantly increased lumbar stiffness.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSequential treatment lumbar stiffness
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Stiffness change
21%
Sequential treatment
Source sentences
Summary
Sequential teriparatide and denosumab led to highly significant (all Ps < 0.001) increases LS trabecular vBMD (43%), other vBMD parameters (15-31%), and stiffness (21%).
3 context sentences(design, population, supporting numbers)
Summary · context
Ancillary analysis of baseline, post-teriparatide, and post-denosumab cQCT scans from a randomized trial of 41 women allocated to teriparatide (20 mcg daily; n = 28) or placebo (n = 11).
Summary · context
After 6 months, those on teriparatide continued for 18 months, and those on placebo switched to teriparatide for 24 months.
Summary · context
After completing teriparatide, 33 enrolled in a Phase 2B extension with denosumab (60 mg every 6 months) for 12 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3542888909
08HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, other lumbar vBMD parameters increased significantly during denosumab after teriparatide.
In plain wordsIn premenopausal women with idiopathic osteoporosis, other lumbar bone-density parameters increased significantly during denosumab after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePost-denosumab other lumbar vBMD parameters
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Statistically significant increases in trabecular vBMD (10%; P < 0.001) and other vBMD parameters (P = 0.03-0.001) were seen after denosumab, while stiffness increased by 7% (P = 0.068).
3 context sentences(design, population, supporting numbers)
Summary · context
Ancillary analysis of baseline, post-teriparatide, and post-denosumab cQCT scans from a randomized trial of 41 women allocated to teriparatide (20 mcg daily; n = 28) or placebo (n = 11).
Summary · context
After 6 months, those on teriparatide continued for 18 months, and those on placebo switched to teriparatide for 24 months.
Summary · context
After completing teriparatide, 33 enrolled in a Phase 2B extension with denosumab (60 mg every 6 months) for 12 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3542888905
09HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In premenopausal women with idiopathic osteoporosis, sequential teriparatide and denosumab significantly increased other lumbar vBMD parameters.
In plain wordsIn premenopausal women with idiopathic osteoporosis, sequential teriparatide and denosumab significantly increased other lumbar bone-density parameters.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSequential treatment other lumbar vBMD parameters
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Other vBMD changes
15 to 31%
Sequential treatment
Source sentences
Summary
Sequential teriparatide and denosumab led to highly significant (all Ps < 0.001) increases LS trabecular vBMD (43%), other vBMD parameters (15-31%), and stiffness (21%).
3 context sentences(design, population, supporting numbers)
Summary · context
Ancillary analysis of baseline, post-teriparatide, and post-denosumab cQCT scans from a randomized trial of 41 women allocated to teriparatide (20 mcg daily; n = 28) or placebo (n = 11).
Summary · context
After 6 months, those on teriparatide continued for 18 months, and those on placebo switched to teriparatide for 24 months.
Summary · context
After completing teriparatide, 33 enrolled in a Phase 2B extension with denosumab (60 mg every 6 months) for 12 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3542888908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.